Connecticut pays $88.17 per Medicaid enrollee for Ocrelizumab, a multiple sclerosis biologic. New York pays $8.72 for the same drug. Same J-code. Same federal program. A 10x gap.

That single comparison captures what six years of Medicaid injectable drug data reveal: a specialty pharmaceutical system where geography, not diagnosis, determines how much a state's program spends on its sickest patients.

The Per-Enrollee Gap Is Wider Than Anyone Assumes

Enrollment-adjusted spending is the right lens for comparing states of vastly different sizes, and when you apply it, the variation is striking. Hawaii's Medicaid program paid $242.91 per enrollee for Epoetin Beta (J0887), a drug used in end-stage renal disease. Arizona paid $29.07 per enrollee for the same drug code. That's an 8x difference for a treatment tied to dialysis, a condition with relatively predictable prevalence.

Pembrolizumab, the cancer immunotherapy, shows a similar pattern. Puerto Rico's Medicaid paid $68.50 per enrollee for the drug, the highest rate among all billing states. California paid $13.36. That's more than a 5x spread across a single oncology agent.

These aren't small-sample anomalies. Puerto Rico's Pembrolizumab total reached $101,550,007 across 10,385 claims. Hawaii's Epoetin Beta spending hit $96,862,387 against a Medicaid enrollment of just 398,753. When a small program spends this much per enrollee on a single injectable, it reflects either concentrated disease burden, pricing differences, or both. The data can't distinguish between those explanations, but the consequence is the same: a Medicaid enrollee's effective access to high-cost biologics is shaped heavily by where they live.

Ultra-Rare Drugs, Ultra-High Costs Per Claim

Some of the starkest numbers involve drugs with very few claims. Pennsylvania paid $155,012,013 for Burosumab-twza (J0584), a treatment for a rare phosphate-wasting disorder, across only 9,912 claims. That works out to $46.06 per enrollee, but the per-claim cost implied by those numbers is extraordinary. Washington State paid $108,690,874 for Emicizumab (J7170), a hemophilia A treatment, across just 3,941 claims at $48.83 per enrollee.

These figures illustrate a structural feature of specialty injectable spending: a handful of ultra-high-cost drugs for rare conditions can dominate a state's J-code budget even when the patient population is tiny. For Medicaid programs operating under fixed actuarial assumptions, a single new rare-disease approval can materially shift per-enrollee costs within months.

Florida's Doxercalciferol (J1270) spending tells a different story. At $227,346,043 total across nearly 1.9 million claims, this is a high-volume, lower-per-claim drug tied to chronic kidney disease management. Florida's 5,211,017 Medicaid enrollees bring the per-enrollee rate to $43.63, but the sheer claim volume signals a program managing a large dialysis-adjacent population at scale.

Organizational Billing Has Effectively Taken Over

Across the highest-spending states, individual providers have been almost entirely displaced from J-code billing. Florida's total J-code spending reached $684,594,717, with organizational providers accounting for 99.87% of that total. Delaware, Minnesota, and Hawaii each showed organizational billing at exactly 100% of J-code spending, with org-to-individual ratios of 661,856.4, 55,748.49, and 24,439.62 respectively.

The Delaware ratio is particularly stark. With $35,204,142 in organizational billing against just $53 from individual providers, the state's injectable drug administration is functionally a closed infusion center system. Minnesota and Hawaii show the same pattern at different scales.

This consolidation matters for access. When specialty injectables flow almost exclusively through organizational billing entities, patients who can't reach an infusion center, whether due to geography, transportation, or scheduling, face a structural barrier that per-enrollee spending figures don't capture. High spending per enrollee and high organizational concentration can coexist with significant unmet need among the patients who never make it to the infusion chair.

Connecticut's Ocrelizumab numbers bring this full circle. At $88.17 per enrollee versus New York's $8.72 for the same multiple sclerosis drug, the gap is large enough that it demands a specific accounting: are Connecticut's negotiated prices higher, is MS prevalence genuinely elevated, or do managed care carve-out arrangements in New York suppress utilization that Connecticut's fee-for-service structure captures? The answer determines whether Connecticut's spending reflects better access or higher prices, and that distinction has direct consequences for every Medicaid enrollee with MS who lives on the wrong side of a state line.